Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth
Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
The study plans to determine the relationship between plasma concentrations of 17-OHPC
(hydroxyprogesterone caproate) and the rate of preterm birth. The study is a randomized, open
label study of pregnant women with one or more prior spontaneous preterm births. Subjects are
randomized to a weekly single injection of either 250 or 500mg 17-OHPC (hydroxyprogesterone
caproate).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Steve N. Caritis, MD
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)